Intellia presented data from its Phase I study of NTLA-2001 at the 2024 American Heart Association scientific meeting in ...
Analysts appear optimistic for Intellia’s gene editor nex-z, which showed a greater serum TTR reduction than Alnylam’s ...
In one of the most closely-watched arenas in biotech, Intellia says its gene editing treatment for a heart muscle ...
Disease markers stabilized or improved in cardiomyopathy patients who received a single dose of Intellia Therapeutics’ in ...
The recent updates from the Phase 1 trials of NTLA-2001, an in-vivo CRISPR/Cas9 based therapy, have shown encouraging results in ATTR-CM and ATTR-PN conditions. These findings, presented at the ...
Healthcare Asia on MSN10h
Global regenerative medicine market to grow by $70.11b by 2028It is driven by developments in personalised medicine, gene therapy, and CRISPR technology. The global regenerative medicine ...
We recently compiled a list of the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2024. In this article, we are going to ...
A breakthrough tool called Helicase-Assisted Continuous Editing (HACE) allows scientists to create precise genetic mutations ...
ARK Investment Management LLC, more commonly known as ARK Invest, is an American investment management firm headquartered in ...
Medpage Today on MSN1d
Novel CRISPR-Cas9-Based Promising in ATTR CardiomyopathyA CRISPR-Cas9-based investigational therapy was linked with a drop in serum transthyretin (TTR) levels in patients with ...
A new study presents "Evo" – a machine learning model capable of decoding and designing DNA, RNA, and protein sequences, from molecular to genome scale, with unparalleled accuracy. Evo's ability to ...
Intellia Therapeutics CEO John Leonard has, for the last couple years, found himself stuck in a financial Groundhog Day.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback